TL;DR: The Centers for Medicare & Medicaid Services modified NCD 156 governing intravenous iron therapy coverage for Medicare beneficiaries, effective March 7, 2026. Here's what billing teams need to do.
CMS updated NCD 156, the National Coverage Determination for intravenous iron therapy, which establishes Medicare coverage policy for IV iron products administered to ESRD patients on chronic hemodialysis. The policy covers two specific drug products — sodium ferric gluconate complex in sucrose injection (covered as first-line therapy since December 1, 2000) and iron sucrose injection (covered since October 1, 2001) — when furnished intravenously to patients also receiving supplemental erythropoietin therapy. No specific HCPCS drug codes are listed in this version of the policy document, which is itself a billing issue worth flagging with your team.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Intravenous Iron Therapy |
| Policy Code | NCD 156 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Nephrology, dialysis facilities, renal dialysis billing, hospital outpatient |
| Key Action | Confirm your billing documentation supports all four coverage criteria — ESRD diagnosis, chronic hemodialysis, IV administration, and concurrent erythropoietin therapy — before submitting claims under NCD 156 after March 7, 2026 |
CMS Intravenous Iron Therapy Coverage Criteria and Medical Necessity Requirements 2026
The core medical necessity framework under NCD 156 is tight and conjunctive — meaning all criteria must be present simultaneously, not just one or two. To qualify for Medicare reimbursement under this coverage policy, the patient must have iron deficiency anemia, be undergoing chronic hemodialysis, receive the iron product intravenously (not orally), and be on supplemental erythropoietin therapy. If any one of those four elements is missing from the clinical documentation, the claim is exposed.
The clinical rationale in the policy is straightforward: oral iron requires GI absorption and is less effective in this population. IV iron goes directly into the bloodstream in a bioavailable form for red blood cell synthesis. CMS has accepted that clinical reality and built the coverage criteria around it. The real billing question isn't whether IV iron is medically sound — it's whether your documentation closes the loop on all four coverage elements every time.
The policy covers two products specifically. Sodium ferric gluconate complex in sucrose injection has been a covered first-line treatment since December 1, 2000. Iron sucrose injection was added as a covered first-line option effective October 1, 2001. Both products are covered in the same clinical context. If your facility uses a different IV iron formulation — ferric carboxymaltose or ferumoxytol, for example — this NCD does not explicitly extend coverage to those agents. That's a prior authorization risk you need to assess separately.
CMS billing guidelines for ESRD-related drug administration involve multiple claim pathways — hospital outpatient, renal dialysis facility, and carrier/MAC claims — and this policy references transmittals across all three. The claims processing instructions point to the Medicare Hospital Manual (TN 773 and TN 763), the Medicare Intermediary Manual (TN 1834 and TN 1812), the Medicare Carriers Manual (TN 1708), and the Medicare Renal Dialysis Facility Manual (TN 91). That spread tells you something: this policy touches multiple billing environments, and the applicable billing guidelines differ by setting.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Iron deficiency anemia in ESRD patients on chronic hemodialysis receiving supplemental erythropoietin — treated with sodium ferric gluconate complex in sucrose injection (IV) | Covered | No codes listed in policy | Covered as first-line treatment effective December 1, 2000 |
| Iron deficiency anemia in ESRD patients on chronic hemodialysis receiving supplemental erythropoietin — treated with iron sucrose injection (IV) | Covered | No codes listed in policy | Covered as first-line treatment effective October 1, 2001 |
| IV iron for ESRD patients not receiving supplemental erythropoietin therapy | Not Established | N/A | Erythropoietin therapy is an explicit coverage condition — absence likely results in denial |
| Oral iron supplementation in hemodialysis patients | Not Covered under NCD 156 | N/A | Policy explicitly distinguishes IV from oral administration; oral products are outside NCD 156 scope |
| IV iron formulations other than sodium ferric gluconate complex or iron sucrose (e.g., ferric carboxymaltose, ferumoxytol) | Not Addressed | N/A | Not named in NCD 156; coverage determination falls outside this NCD; may require prior auth or separate LCD review |
CMS Intravenous Iron Therapy Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your documentation requirements before March 7, 2026. Every claim submitted under NCD 156 needs to support all four elements: ESRD diagnosis, chronic hemodialysis, IV route of administration, and concurrent erythropoietin therapy. Build a documentation checklist if you don't already have one and run it against a sample of recent claims before the effective date. |
| 2 | Identify which IV iron products your facility is administering. NCD 156 explicitly names sodium ferric gluconate complex in sucrose injection and iron sucrose injection. If your clinical team is administering ferric carboxymaltose, ferumoxytol, or ferric derisomaltose, those products are not covered under this NCD. Flag those cases for your compliance officer and determine whether a separate coverage pathway applies. |
| 3 | Confirm your billing setting matches the correct claims processing transmittal. NCD 156 references six separate transmittals across hospital, intermediary, carrier, and renal dialysis facility billing environments. Your charge capture and claim routing should align with the setting where the service is furnished — outpatient hospital, freestanding dialysis facility, or physician office. A mismatch here is a mechanical denial waiting to happen. |
| 4 | Flag the missing HCPCS codes in your coding workflow. The policy document as published does not list specific HCPCS drug codes. This doesn't mean codes don't exist — Q4081, Q0138, and similar HCPCS codes for IV iron products have historically been used in this context — but it does mean your coding team should verify the applicable HCPCS codes through your MAC's billing guidelines and the current HCPCS Level II code set, not NCD 156 alone. If you're unsure which codes to attach, talk to your billing consultant before the March 7, 2026 effective date. |
| 5 | Check your LCD landscape for anything that overrides or supplements this NCD. NCDs set the floor, but Local Coverage Determinations from your MAC can impose additional requirements. If your MAC has an active LCD touching IV iron therapy or ESRD drug administration, those requirements layer on top of NCD 156 and can affect reimbursement and claim denial exposure. |
| 6 | Review erythropoietin documentation separately. The coverage condition is that the patient is "receiving supplemental erythropoietin therapy" — not merely prescribed it. If EPO therapy was discontinued or interrupted, document that clearly and evaluate whether the IV iron claim is still supportable under this NCD for that date of service. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Intravenous Iron Therapy Under NCD 156
The policy document for NCD 156 does not list specific CPT, HCPCS, or ICD-10 codes. This is the part where billing teams need to pay attention.
The absence of codes in the NCD itself is not unusual — many NCDs are written at the clinical indication level and leave code-level guidance to claims processing transmittals and MAC-specific billing guidelines. But it does mean you cannot rely solely on this document to build your charge capture.
What to Do Instead
Cross-reference the six claims processing transmittals listed in the policy (TN 773, TN 763, TN 1834, TN 1812, TN 1708, TN 91) against your current HCPCS code set for IV iron drug administration. Historically relevant HCPCS codes in this clinical area include drug administration codes for iron-containing injectable products, but those should be verified against current CMS fee schedule data and your MAC's billing guidelines — not assumed from a prior year.
For ICD-10 diagnosis coding, iron deficiency anemia in the context of chronic kidney disease and ESRD has specific code pathways. Your coding team should map the relevant diagnosis codes and confirm they align with what the policy describes as the covered indication — iron deficiency anemia in ESRD patients on hemodialysis.
If your coding team doesn't have a current crosswalk between the clinical criteria in NCD 156 and the applicable HCPCS and ICD-10 codes used in your billing system, build that now. Don't wait until a claim denies in April to discover the gap.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.